Riskpilot← Back to searchSign inGet full accessGloMedica AB
ABActiveOrg 5568799463Banergränden 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20120 employees
Revenue 2024
SEK 1,5M
+16% vs 2023
EBITDA margin
86.1%
0% vs 2023
Equity ratio
33.9%
Financial strength
Net profit 2024
SEK 775K
-7% vs 2023
| Revenue | SEK 1,5M | +16% |
| EBITDA | SEK 1,3M | +0% |
| Net profit | SEK 775K | -7% |
| Total assets | SEK 10,1M | +4% |
| Equity | SEK 3,4M | +29% |
| Employees | 0 | — |
Legal name
GloMedica AB
Org number
5568799463
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 januari 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva läkararbete samt utbildning och forskning inom arbetsområde vård och hälsa, medicin, naturvetenskap, teknologi och IT. Aktiebolaget ska vidare äga och handla med värdepapper och fastigheter samt därmed förenlig verksamhet. Aktiebolaget ska därutöver vara arrangör och medarrangör vid evenemang och därmed förenlig verksamhet.
Address
Banergränden 6
Phone
+46709757849
Email
ilkaanker@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 867 | 844 | 1 141 | 1 288 | 1 497 |
| Staff expenses | — | — | −121 | −102 | −116 |
| EBITDA | 550 | 613 | 859 | 1 287 | 1 289 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 550 | 613 | 859 | 1 287 | 1 289 |
| Net financials | −49 | −11 | 11 | 53 | −105 |
| Profit before tax | 407 | 508 | 700 | 1 059 | 985 |
| Tax | −94 | −106 | −142 | −221 | −210 |
| Net profit | 313 | 402 | 558 | 838 | 775 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 224 | 3 528 | 6 939 | 9 735 | 10 079 |
| Equity | 849 | 1 250 | 1 808 | 2 646 | 3 421 |
| Long-term debt | 1 522 | 1 505 | 3 711 | 5 331 | 4 845 |
| Short-term debt | 293 | 116 | 594 | 651 | 508 |
| Total debt | 1 815 | 1 621 | 4 306 | 5 982 | 5 353 |
EBITDA margin
86.1%
This company
15.8%
Market median
+445% vs market
20202024
Equity ratio
33.9%
This company
38.2%
Market median
+11% vs market
20202024
Return on equity
22.7%
This company
18.4%
Market median
+23% vs market
20202024
Net profit margin
51.8%
This company
8.1%
Market median
+540% vs market
20202024
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20202024
Debt / equity
1.95×
This company
0.62×
Market median
-215% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IL Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GloMedica AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ilka Leoni Magdalena Anker | Chief Executive Officer | 0 companies |
| Hans Christian Anker-Hansen | Board of Directors | 0 companies |